BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

Lilly's Jaypirca Combination Cuts Disease Progression Risk by 45% in Relapsed CLL Phase 3 Trial

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the...

June 16, 2026 | News

Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data

Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...

June 15, 2026 | News

Good Enough and Cheap, or Prove It's Equivalent? Asia's Biosimilar Trust Gap

There is a number that captures Asia's biosimilar paradox in a single line. According to Samsung Bioepis's quarterly tracking of the United States market, ...

June 15, 2026 | Analysis

Windward Bio Doses First Patients in Phase II COPD Trial of SKB378/WIN378

COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease SKB378/WIN378 is currently being evaluated in the Phase ...

June 11, 2026 | News

Can the 'Pharmacy of the World' Survive Its Own Scandals?

In late September and early October 2025, children in the central Indian state of Madhya Pradesh began arriving at hospitals with the same grim trajectory:...

June 08, 2026 | Analysis

Curative but Unaffordable: Gene and Cell Therapy's Access Paradox in Asia

At almost every cell-and-gene-therapy conference in the region, the same slide appears: a child who was dying of leukaemia, now in durable remission; a tee...

June 03, 2026 | Analysis

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...

June 02, 2026 | Analysis

Innovation Powerhouse or Inflated Bubble? Reading China’s First-in-Class Boom

A decade ago, the phrase “Chinese first-in-class drug” would have drawn a raised eyebrow in any Western boardroom. China made generics, copied ...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

When America Builds a Wall: Who Inherits China’s Displaced Biotech Work?

When President Trump signed the FY2026 National Defense Authorization Act on December 18, 2025, the biopharmaceutical industry finally got the law it had s...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

Leads Biolabs Secures China Phase III Approval For Opamtistomig In First Line EP NEC Treatment

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibod...

May 20, 2026 | News

Ferring Pharmaceuticals Reports Real World Evidence Supporting ADSTILADRIN Re Induction In BCG Unresponsive Bladder Cancer

Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial non-responders with Bacillus Calmette-Guérin (BCG)-unresponsive n...

May 19, 2026 | News

AstraZeneca And Daiichi Sankyo Expand ENHERTU Into Early HER2 Positive Breast Cancer Treatment In The US

Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial ...

May 19, 2026 | News

Akeso, Inc. Highlights Promising Phase II AML Data For Ligufalimab Combination At EHA 2026

Akeso, Inc. announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will ...

May 18, 2026 | News

Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the prelimina...

May 13, 2026 | News

Stay Connected